HSP90 inhibitors such as geldanamycin and its derivatives target HSP90 N terminus and block its ATPase activity; they have been identified as potential treatment strategy in cancer and promising drugs for immune and inflammatory diseases, including diabetes (46). This evidence concerns the gene HSP90AB1 and diabetes mellitus.